Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Avita Medical (RCEL – Research Report). The associated price target was lowered to $12.50.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Josh Jennings has given his Buy rating due to a combination of factors including Avita Medical’s strong growth potential and its strategic product launches. Despite a slight miss in first-quarter sales compared to market expectations, the company demonstrated impressive year-over-year revenue growth of 67%, driven by the deployment and adoption of its RECELL Go system.
Avita’s management remains confident in its 2025 revenue guidance, projecting substantial growth with new products like RECELL Go mini and Cohealyx expected to significantly contribute to future sales. The company’s robust gross margin and strategic expansion into new accounts further support the positive outlook, making Avita Medical a compelling investment opportunity according to Jennings.